Scotiabank Initiates Coverage On BridgeBio Pharma with Sector Outperform Rating, Announces Price Target of $44
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on BridgeBio Pharma with a Sector Outperform rating and set a price target of $44.
October 16, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has initiated coverage on BridgeBio Pharma with a Sector Outperform rating and a price target of $44, indicating a positive outlook.
The initiation of coverage with a Sector Outperform rating and a specific price target of $44 by Scotiabank suggests a positive outlook for BridgeBio Pharma. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100